N/A
N=20
Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease
Peripheral Artery Disease
Bottom Line
View on ClinicalTrials.gov: NCT03099369 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcome: Primary: Change in the Mean Daily Walking Distance Over 7 Consecutive Days — 754.2; -1160 steps
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Daily Step-based Exercise (Behavioral); Symptom-based Exercise (Behavioral); Fitbit Fitness Monitor (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of North Carolina, Chapel Hill
- Primary completion
- Dec 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in the Mean Daily Walking Distance Over 7 Consecutive Days |
754.2; -1160 | — |
| SECONDARY Change in the Peripheral Artery Questionnaire (PAQ) Summary Score |
— | — |
| SECONDARY Change in the Vascular Quality of Life Questionnaire (VascuQol) Summary Score |
— | — |
Summary
Peripheral artery disease (PAD) is caused by blockages in the leg arteries. PAD limits patients' walking ability and quality of life. For patients with PAD, home exercise programs can improve walking ability and quality of life. In many patient populations, walking more than 5,000 steps a day is associated with better health. Currently, the benefit of walking more than 5,000 steps a day in patients with PAD has not been well studied.
The purpose of this clinical trial is to compare two different home exercise programs in patients with PAD: walking at least 5,000 steps a day with the help of fitness monitors vs. walking 45 consecutive minutes for 3 to 5 days a week (a common exercise prescription for PAD). This study has the potential to demonstrate that, with the help of fitness monitors, walking at least 5,000 steps a day can improve walking ability and quality of life for patients with PAD.
Eligibility Criteria
Inclusion Criteria
- Male or female, age 18 years or older
- Diagnosis of lower extremity PAD based on at least 1 of the following criteria:
- Ankle-brachial index (ABI) of 0.9 or less in one or both legs
- Invasive angiography demonstrating obstructive lower extremity artery disease
- Endovascular or surgical revascularization of lower extremity artery
- Symptomatic lower extremity PAD, characterized by 1 of the following:
- Fontaine Stage IIa: intermittent claudication after walking > 200 meters
- Fontaine Stage IIb: intermittent claudication after walking < 200 meters
- Have the availability of a suitable environment in which to walk
- Have a mobile phone with WiFi and Bluetooth capability
- Have the ability to read and speak the English language
Exclusion Criteria
- Wheelchair bound
- Use of a walking aid (ie. cane, crutches, walker, motorized chair)
- Below or above the knee amputation
- Leg pain at rest
- Acute or critical limb ischemia
- Ischemic ulceration or gangrene
- Diabetes mellitus complicated by neuropathy
- Walking impairment due to another cause than PAD
- Ongoing evaluation for coronary artery disease (ie. awaiting a stress test or cardiac catheterization)
- Active coronary artery disease requiring the initiation or uptitration of an anti-anginal medication
- Angina with Canadian Cardiovascular Society (CCS) class 3-4 symptoms
- Myocardial infarction in the last 3 months
- Active congestive heart failure requiring the initiation or uptitration of diuretic therapy
- Congestive heart failure with New York Heart Association (NYHA) class 3-4 symptoms
- Active arrhythmia requiring the initiation or uptitration of an anti-arrhythmic medication
- Severe valve disease
- Active cancer or malignancy (not in remission)
- End-stage renal disease requiring hemodialysis or peritoneal dialysis
- Advanced liver disease, defined as cirrhosis
- Thyroid disease with abnormal TSH in the past 3 months
- Severe cognitive dysfunction, defined as dementia
Data sourced from ClinicalTrials.gov (NCT03099369). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.